Physician profile
Doris Lin
NPI 1952338642
$3,797.33
in general payments reported to CMS, 2019-2025
11 companies · $3,497 in 2025
The $3,497 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.83 · 2021: $126 · 2022: $20.05 · 2023: $73.41 · 2025: $3,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $3,460 · Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $3,460.00 |
| Food and Beverage | $110.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acteon INC | $3,460.00 | 2025 | 2 F55542 Sp Newtron Led Module Only Sn 1826680052, Sn 1826680056 |
| Intersect Ent, INC. | $75.31 | 2019-2021 | |
| Stryker Corporation | $75.23 | 2021 | |
| Integra Lifesciences Corporation | $48.17 | 2023 | Integra, Integra Duo, Codman Isocool Aht |
| Mallinckrodt Hospital Products INC. | $30.14 | 2021 | |
| Acclarent, INC | $25.24 | 2023 | Acclarent Aera |
| Glaxosmithkline, LLC. | $22.76 | 2025 | Trelegy Ellipta |
| Genzyme Corporation | $20.05 | 2022 | |
| Hikma Pharmaceuticals USA | $14.70 | 2025 | Ryaltris |
| Optinose US, INC. | $14.40 | 2019 | |
| Phadia US INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.